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Objective: The genetic polymorphism concerning the ß3-subunit of platelet integrin receptor glycoprotein IIIa is
held responsible for enhanced binding of adhesive proteins resulting in increased thrombogenic potential. Whether
it is associated with mortality, HbA1c or platelet volume is tested prospectively in an epidemiological cohort.
Research design and methods: Population-based Cooperative Health Research in the Region of Augsburg (KORA)
S4-Survey (N = 4,028) was investigated for prognostic value of PLA1A2-polymorphism regarding all-cause mortality,
correlation with HbA1c, and mean platelet volume. Multivariate analysis was performed to investigate association
between genotype and key variables.
Results: Prevalence of thrombogenic allele variant PLA2 was 15.0%. Multivariate analysis revealed no association
between PLA1A2 polymorphism and mortality in the KORA-cohort. HbA1c was a prognostic marker of mortality in
non-diabetic persons resulting in J-shaped risk curve with dip at HbA1c = 5.5% (37 mmol/mol), confirming previous
findings regarding aged KORA-S4 participants (55–75 years). PLA1A2 was significantly associated with elevated
HbA1c levels in diabetic patients (N = 209) and reduced mean platelet volume in general population. In non-diabetic
participants (N = 3,819), carriers of PLA2 allele variant presenting with HbA1c > 5.5% (37 mmol/mol) showed higher
relative risk of mortality with increasing HbA1c.
Conclusion: PLA1A2 polymorphism is associated with mortality in participants with HbA1c ranging from 5.5%
(37 mmol/mol) to 6.5% (48 mmol/mol). Maintenance of euglycemic control and antiplatelet therapy are therefore
regarded as effective primary prevention in this group.
Keywords: Glycated hemoglobin, Platelet glycoprotein receptor polymorphism, Mean platelet volume, All-cause
mortality, Glycemic management, EpidemiologyBackground
Platelets play an important role in primary hemostasis
and are involved in atherosclerosis and atherothrombotic
events. Inhibition of platelet aggregation is the key step
of any treatment of vascular disease. Metabolic conditions
like hyperglycemia influence platelet reactivity and the
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article, unless otherwise stated.and by glycation of platelet proteins, especially in type
2 diabetes. Increased platelet reactivity involves intensi-
fied adhesion and aggregation in patients with diabetes
mellitus or those at high risk for the disease [1]. A sub-
population of large, hyperactive platelets circulates in
these patients, at a level similar to that predicted from
the results of patients who have experienced myocardial
infarction [2]. This suggests that the elevated potential
for aggregation of such platelets lowers their threshold
for activation, thus contributing to the increased incidence
of acute cardiovascular events in diabetes mellitus. As a
determinant of platelet activation mean platelet volumetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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[3]. The increase in MPV may precede acute myocardial
ischemia, acute myocardial infarction, coronary athero-
sclerosis, the presence and the short-term prognosis and
the long-term risk of stroke and thus is in association with
major cardiovascular events [4]. Case–control studies have
documented significant positive associations of MPV with
type 2 diabetes mellitus [5], pre-diabetes, obesity, and
other metabolic risk factors, whereas smaller platelets
are detected in chronic inflammatory disease, inflammatory
bowel disease or rheumatoid arthritis [6]. The platelet
count is inversely related to the MPV, patients with low
MPV present with higher numbers of platelets and vice
versa [7-9].
In a study on Japanese subjects MPV in patients with
prediabetes was shown to be higher if compared to normal
subjects, and it was positively associated with levels of
fasting blood glucose in prediabetic and normal subjects
[10]. In a Korean study MPV had a significant positive
relationship with FPG after adjusting for diabetes in
women as a confounding factor pointing out a gender
specifity. The positive relationship between an increased
glucose level and increased MPV was shown to be a
unique phenomenon of diabetes itself. [11]. MPV values
seem to be influenced by antidiabetic therapy, MPV is
increased in patients with uncontrolled type 2 diabetes
mellitus, and was significantly higher in diabetic patients
treated with oral hypoglycemic therapy than in those
patients on insulin therapy [12].
Numerous polymorphic surface glycoprotein receptors
are responsible for platelet functionality with membrane
glycoprotein (GP) IIb/IIIa playing a major role in platelet
function. It enables stimulated platelets to bind to fi-
brinogen and related adhesive proteins, a process that
is considered central in the development of thrombosis.
The gene encoding GPIIIa shows a common platelet
antigen polymorphism [PLA1A2, (ITGB3 rs5918)] at pos-
ition 1565 in exon 2 of the coding region for glycoprotein
IIIa and results in a leucine-proline exchange [13]. The
presence of the PLA2 allele was first reported in 1996 to
be associated with an increased risk of coronary heart
disease (CHD) [14]. The importance of the GPIIb/IIIa
receptor has been further supported by clinical trials in
which GPIIb/IIIa antagonists have been shown to reduce
restenosis rate after angioplasty and to reduce the mor-
bidity and mortality associated with unstable angina,
high-risk coronary angioplasty, and acute myocardial
infarction [15]. Studies on the PLA1A2-polymorphism
and coronary risk suggest an influence of the PLA2 allele
on the clinical phenotype and the interaction with other
environmental factors [16]. The hyperaggregability associ-
ated with the PLA2 allele has been linked to an increased
surface expression of GPIIb/IIIa receptors and increased
affinity for fibrinogen [17]. The result of this alteredexpression is discussed controversially; because some
studies suggest an association of the PLA2 allele with a
greater risk of coronary events others do not support
this assumption [18,19]. In particular, the strongest effect
of the PLA2 allele was expressed on the risk of occlusion
after revascularization procedures, mainly after stent
implantation [20]. Some more recently published analyses
do not support this hypothesis [21]. Hyperresponsiveness
to agonists has been demonstrated in platelets positive for
the PLA2 allele in vitro [16,17]. In a mechanism possibly
unrelated to its effect on platelet reactivity to aggregating
stimuli, the presence of the PLA2 allele might influence
the antiaggregatory effect of platelet inhibitory drugs
such as acetylsalicylic acid (ASA), clopidogrel, and GPIIb/
IIIa antagonists [17]. Studies evaluating healthy donors
indicate a possible role of the PLA2 allele in ASA resist-
ance based on measures of platelet function, particularly
in patients homozygous for PLA2 [22].
Beside the inconsistent reports on the predictability of
the PLA polymorphism on cardiovascular events Tschoepe
and coworkers found a significant association with the
metabolic condition of type 2 diabetes mellitus in an
analysis of 112 consecutive patients additionally classified
according to the presence of macrovascular disease
published earlier [23]. This finding is in contrast to a
later publication of Maerz and coworkers from the
Ludwigshafen Risk and Cardiovascular Health Study
which revealed no association of the GPIIIa PLA1A2
polymorphism with type 2 diabetes, glucose metabolism,
angiographically proven CHD or myocardial infarction [24].
With this regard, the aim of this prospective analysis
of the KORA S4-survey is to clarify 1) the predictive role
of the PLA1A2 polymorphism in the general population
in terms of all-cause mortality, 2) its relation with HbA1c,
and 3) its relation with main characteristics of platelet
morphology.
Research design and methods
Study population
The KORA study region consists of the city of Augsburg
and the two surrounding districts with about 600,000
inhabitants in 1999. The Bavarian ethic committee
approved the KORA S4 study (conducted between 1999
and 2001) which followed the declaration of Helsinki;
informed consent was given by each participant. The
initial study sample involved 6,640 subjects randomly
drawn from the general population. Altogether 4,261
subjects participated in the baseline study (response
67%). Of those, 4,028 had been characterized according
their PLA1A2 polymorphism by a flow cytometry based
assay as described elsewhere [25] and could be included
in the present analysis. Briefly, the polymorphism was
determined from frozen EDTA cell samples by flow
cytometry analysis using the stereospecific monoclonal
Stratmann et al. Cardiovascular Diabetology 2014, 13:90 Page 3 of 9
http://www.cardiab.com/content/13/1/90antibody SZ21 directed against the ß3-subunit of the
GPIIb/IIIa receptor. Mortality was followed up for a
maximum of 10 years and cause of death was coded using
common ICD coding. Blood collection and processing
was described earlier [26]. Diabetes was defined based on
self-reported physician diagnosis, use of antidiabetic
agents and/or HbA1c levels at baseline ≥6.5% (48 mmol/
mol) (N = 209 participants) [27]. HbA1c was determined
centrally at baseline [26]. HbA1c-values were determined
using a turbidimetric immunologic assay (Tina-quant,
Roche Diagnostics). The interassay coefficients of vari-
ation were 3.9% at HbA1c 5.7% (39 mmol/mol) and
5.2% at HbA1c 9.7% (83 mmol/mol).
Descriptive analysis results of the population charac-
teristics were reported as mean ± standard deviation
(SD). Comparison between the groups was done by
Mann–Whitney testing or one-way ANOVA followed by
Dunnett’s multiple comparison post-test for continuous
data and Fisher’s exact test for categorical data.
A multivariate logistical regression model was used to
evaluate the cross-sectional association of genotype with
HbA1c, MPV, platelet mass and platelet count. Variables
investigated for possible confounding included age,
sex, BMI, waist-hip ratio, diastolic and systolic blood
pressure, cholesterol levels (total, HDL, and LDL),
smoking status (categorized: non-smoker, former smoker,
current smoker), high alcohol intake (categorized: ≥20 g/
day for women; ≥40 g/day for men), leisure time physical
activity (categorized: >1 h per week). Association between
platelet count and covariates were investigated by linear
regression model.
Cox proportional hazards model was used for a multi-
variate analysis of the risk of overall death with geno-
types, HbA1c level and platelet morphology (MPV, platelet
count, and platelet mass), taking the same adjustment as
previously described. Statistical analysis was done using R
version 2.15.1 (The R Foundation for Statistical Comput-
ing). P values <0.05 were regarded statistically significant.
Results
Population characteristics and genotype distribution
4,261 subject data were available for evaluation from the
KORA S4-survey. 4,028 subjects had been characterized
according to their HbA1c, PLA1A2 genotype was deter-
mined by flow cytometry and data on the survival status
were available. Total prevalence of the PLA2 allele was
15.0%, genotype distribution was as follows: A1A1:
2,912/4,028 = 72.3%, A1A2: 1,027/4,028 = 25.5%, A2A2:
89/4,028 = 2.2%. For evaluating the role of the PLA1A2
genotype two groups were set up comprising A1A1
genotypes and A1A2/A2A2 genotypes, called AxA2.
We detected no significant difference in prevalence of
AxA2 genotype in the living and deceased participants
(Table 1). The other variables which differed betweenliving and deceased people, such as diabetes prevalence,
age, BMI, were taken as covariates in the following
multivariate analysis.
Antidiabetic regimen was similar in the groups A1A1
and AxA2: Prevalence of a combination therapy with
oral antidiabetics and insulin was 9% in A1A1 and 11%
in AxA2, insulin therapy was more often in A1A1 (13%)
than in AxA2 (11%), 40% of A1A2 participants received
oral antidiabetics only, whereas in the AxA2 group this
therapeutic regimen was followed by 38%, the remaining
participants in the groups did not receive any antidiabetic
medication. Participants with diabetes significantly received
more often acetylsalicyl acid than non-diabetics (25.0% vs
5.3%), but the application of acetylsalicyl acid did not differ
between the groups A1A1 and AxA2. Regarding antidia-
betic and antithrombotic therapy a possible confounding
between the groups A1A2 and AxA2 therefore is not to
be expected.
Mean diabetes duration did not differ statistically signifi-
cant in both groups (A1A1 and AxA2) (9.3 ± 8.1 years vs.
9.5 ± 7.9 years, respectively).
PLA1A2 genotype association with HbA1c and MPV
An association of PLA1A2 genotype with diabetes mellitus
type 2 was suggested from our previous publication
[23]. Taking into account only individuals with diabetes
(diagnosed diabetes or HbA1c ≥6.5% (48 mmol/mol),
N = 209), an association between PLA1A2 and elevated
HbA1c levels could be found (Table 2). However, no sig-
nificant association between HbA1c and genotype AxA2
was found regarding the whole cohort (4,028 participants)
after multivariable adjustment (Table 2).
A significant association between genotype AxA2 and
lower MPV was demonstrated in the whole cohort and the
group of non-diabetic people, but there was no significant
association for platelet mass and platelet count (Table 2).
Furthermore, a strong correlation of MPV with platelet
count (r = −0.42, p < 0.0001) was detected. No significant
correlation of MPV and platelet mass (r = 0.01, p = 0.53)
was found. Age (β = −0.003, p = 0.015), HbA1c (β = 0.108,
p < 0.0001), BMI (β = 0.023, p < 0.0001), waist-hip-ratio
(β = −1.816, p < 0.0001) were significantly associated
with MPV in multivariate linear regression model.
PLA1A2 genotype association with all-cause mortality
Within 10 years 239 (5.9%) patients died: 167 (5.7%) in
the A1A1, 72 (6.5%) in the AxA2 (68 (6.6%) in the A1A2
and 4 (4.5%) in the A2A2) group, mainly due to cardio-
vascular diseases like myocardial infarction and ischemic
heart disease (49%) as well as cancer (39%). No significant
impact of genotype or HbA1c on overall death was found
(AxA2: adjusted HR (95% CI) =1.17 (0.59, 2.32); HbA1c:
adjusted HR (95% CI) =1.05 (0.83, 1.33)) regarding all
participants.
Table 1 Population characteristics
Surviving persons Deceased persons P
N [subjects] 3,789 239
No. of diabetic subjects 156 (4.1%) 53 (22.2%) <0.0001
GenotypeAxA2 [%] 27.6% 30.1% >0.05
Age [years] 48.2 ± 13.7 63.3 ± 9.7 <0.0001
range : 54–75 years range : 35–75 years
BMI [kg/m2] 27.1 ± 4.6 28.6 ± 4.7 <0.0001
Waist to hip-ratio 0.864 ± 0.088 0.932 ± 0.083 <0.0001
Blood pressure diastolic [mm Hg] 80.3 ± 10.4 80.9 ± 11.3 >0.05
Blood pressure systolic [mm Hg] 127.7 ± 19.0 139.6 ± 22.1 <0.0001
HbA1c [%] 5.55 ± 0.58 5.90 ± 0.95 <0.0001
HbA1c [mmol/mol] 37.2 ± 6.3 41.0 ± 10.4
FBG [mg/dl] 106.6 ± 33.1 118.0 ± 42.9 <0.0001
(1,428 subjects) (201 subjects)
Total cholesterol [mg/dl] 226.7 ± 43.3 235.6 ± 49.5 0.0014
HDL cholesterol [mg/dl] 57.8 ± 17.0 55.9 ± 16.8 >0.05
LDL cholesterol [mg/dl] 136.6 ± 41.4 145.7 ± 42.9 0.0012
Mean platelet volume [fl] 8.722 ± 0.94 8.834 ± 1.066 0.061
Platelet count [/nl] 244.4 ± 57.3 220.9 ± 65.4 0.0001
Platelet mass 2,108 ± 450 1,924 ± 519 0.0001
Analysis results of the population characteristics are reported as mean ± standard deviation (SD). Comparison between the groups are calculated by Mann–Whitney
testing or one-way ANOVA followed by Dunnett’s multiple comparison post-test for continuous data and Fisher’s exact test for categorical data.
Table 2 HbA1c level and platelet morphology in the participants according to diabetic state and PLA1A2 polymorphism
Values Logistic regression
All (N = 4,028) A1A1 (mean ± SD) AxA2 (mean ± SD) Odds ratio (95% CI) P
HbA1c [%] 5.56 ± 0.58 5.60 ± 0.71 1.03 (0.96, 1.11) 0.42
HbA1c [mmol/mol] 37.3 ± 6.3 37.7 ± 7.8
MPV [fl] 8.76 ± 0.96 8.66 ± 0.89 0.90 (0.83, 0.96) 0.003
Platelet mass 2,100 · 2 ± 454.4 2,090.4 ± 460.8 0.99 (0.92, 1.07) 0.75
Platelet count [nl] 242.7 ± 58.3 243.9 ± 57.4 1.03 (0.96, 1.12) 0.33
Diabetes (N = 209)
HbA1c [%] 7.04 ± 1.41 7.63 ± 1.64 1.19 (1.04, 1.35) 0.01
HbA1c [mmol/mol] 53.4 ± 15.4 68.9 ± 8.9
MPV [fl] 9.02 ± 1.07 8.97 ± 0.96 1.03 (0.76, 1.38) 0.86
Platelet mass 1,996.80 ± 516.49 1,979.13 ± 420.85 0.93 (0.67, 1.30) 0.70
Platelet count [nl] 224.97 ± 65.86 223.20 ± 52.06 0.91 (0.66, 1.25) 0.57
Non-Diabetes (N = 3,819)
HbA1c [%] 5.48 ± 0.35 5.48 ± 0.36 0.97 (0.85, 1.11) 0.69
HbA1c [mmol/mol] 36.4 ± 3.8 36.4 ± 3.9
MPV [fl] 8.74 ± 0.95 8.64 ± 0.89 0.89 (0.83, 0.96) 0.002
Platelet mass 2,105.76 ± 450.22 2,096.83 ± 462.37 0.99 (0.91, 1.07) 0.85
Platelet count [nl] 243.61 ± 57.72 245.11 ± 57.46 1.04 (0.97, 1.12) 0.26
The estimates are shown as the adjusted odds ratio with 95% confidence interval (CI) for every unit increase of HbA1c. Model was adjusted for age, sex, waist-hip
ratio, blood pressure (diastolic and systolic), cholesterol (total, HDL, LDL), smoking status (categorized: non-smoker, former smoker, current smoker), alcohol intake
categorized: ≥20 g/day for women; ≥40 g/day for men), physical activity (categorized: >1 h per week).
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Investigating the prediction of all cause of death by HbA1c,
genotype and platelet morphology (MPV, platelet count,
and platelet mass) in the non-diabetic participants
(HbA1c < 6.5% (48 mmol/mol)), we confirmed HbA1c =
5.5% (37 mmol/mol), which was reported by Kowall et al.
regarding KORA S4 participants aged from 55 to 75 years
[28], as a cut-off for positive correlation between HbA1c
level and risk of all-cause mortality, but PLA1A2 poly-
morphism was not significantly associated with overall
cause of death in this group (Table 3). HbA1c was a
strong predictor of survival in non-diabetic subjects
with HbA1c > 5.5% (37 mmol/mol), but was not related
to survival in subjects with HbA1c ≤ 5.5% (37 mmol/mol)
(Table 3). However, in participants with HbA1c ≤ 5.5%
(37 mmol/mol) platelet count and platelet mass, but not
MPV were associated with all-cause mortality (Table 3).
We further analyzed the association of mortality with
HbA1c and platelet morphology (MPV, platelet count,
and platelet mass) in separated genotypes to investigate
possible genotype-specific effects (Table 4). In non-diabetic
participants HbA1c > 5.5% (37 mmol/mol) up to <6.5%
(48 mmol/mol) a significant positive relation was found
between HbA1c level and all-cause mortality only in people
with AxA2 genotype (Table 4), pointing to a combined
effect of HbA1c and AxA2 genotype in this subgroup.
For the participants with HbA1c ≤ 5.5% (37 mmol/mol),
HbA1c was not significantly associated with mortality
(Table 4). Non-significant negative associations of HbA1c
level and risk of mortality were found in both genotype
groups, which might imply higher risk of mortality
in subjects with low level of HbA1c (HbA1c < 5.5%
(37 mmol/mol)) (Table 4). In participants with geno-
type A1A1 and HbA1c < 5.5% (37 mmol/mol), platelet
count, platelet mass and MPV were associated with
the all-cause mortality (Table 4).
The hazard ratios of all-cause mortality in each decile
of HbA1c level in all participants with different geno-




HR (95% CI) P
Genotype AxA2 0.87 (0.54, 1.41) 0.57
HbA1c 0.67 (0.24, 1.83) 0.43
Platelet count 1.03 (1.00, 1.07) 0.03
Platelet mass 1.00 (0.99, 1.00) 0.03
MPV 2.13 (0.98, 4.60) 0.06
The hazard ratios (HR) with 95% confidence interval (CI) for every unit increase of t
mortality and genotype, HbA1c and platelet markers, were taken with adjustment o
(total, HDL, LDL), smoking status (categorized: non-smoker, former smoker, current
men), physical activity (categorized: >1 h per week).is presented in Figure 1, corresponding data are shown
in Table 5. The participants with genotype AxA2 had a
high increase rate in relative risk from HbA1c = 5.5%
(37 mmol/mol) to higher HbA1c, while in participants with
genotype A1A1, the increase was much less pronounced.
In the highest decile (HbA1c > 6.0% (42 mmol/mol)), the
adjusted hazard ratio (95% CI) was 2.97 (1.07, 8.24) in
people with genotype AxA2 compared to 1.35 (0.73, 2.51)
in people with A1A1.
Discussion
Atherosclerosis results from complex interactions between
the environment and genetic factors. Individual hemostatic
platelet response may be influenced by the genetic profile
of the platelet membrane glycoprotein (GP) receptors. As
part of von Willebrand factor and fibrinogen receptor
GPIIIa plays a pivotal role in platelet aggregation. Numer-
ous polymorphisms in platelet surface glycoproteins have
received particular interest [29]; one of those being the
PLA1A2 polymorphism resulting in an exchange at the
amino terminus of the ß3 subunit of the platelet fibrino-
gen receptor glycoprotein GPIIb/IIIa. Furthermore, the
PLA2 allele has been associated with resistance to the
antiplatelet agent such as aspirin [17]. Several lifestyle
parameters like cholesterol-levels, physical activity,
smoking habits and intake of alcohol were included in
our analysis model to take into consideration the con-
founding potential on platelet morphology as described
by Monteiro et al. [30]. In both groups, A1A1 as well as
AxA2, hypoglycemic therapy was comparable, therefore,
effects of antidiabetic medication on platelet morphology
can be neglected. The analysis of the KORA cohort
revealed no association between the PLA1A2 poly-
morphism and all-cause mortality and is thus confirma-
tory to the studies involving larger subject numbers.
Our analysis revealed a non-linear relationship between
HbA1c and mortality in non-diabetic subjects and confirms
previously published results regarding older participants
of KORA S4.atelet morphology in non-diabetic participants
5.5% < HbA1c < 6.5%
(37 mmol/mol < HbA1c < 48 mmol/mol)
(N = 1,627)
HR (95% CI) P
0.99 (0.66, 1.53) 0.97
2.47 (1.04, 5.88) 0.04
0.99 (0.96, 1.02) 0.67
1.00 (0.995, 1.003) 0.95
1.03 (0.51, 2.08) 0.93
he variables are shown. Multivariate analysis of the association between
f age, sex, waist-hip ratio, blood pressure (diastolic and systolic), cholesterol
smoker), alcohol intake (categorized: ≥20 g/day for women; ≥40 g/day for
Table 4 Association of mortality with HbA1c and platelet morphology in non-diabetic participants according to PLA1A2
polymorphism
HbA1c ≤5.5% 5.5% < HbA1c < 6.5%
(HbA1c ≤37 mmol/mol) (37 mmol/mol < HbA1c < 48 mmol/mol)
A1A1(N = 1,597) AxA2(N = 595) A1A1(N = 1,167) AxA2(N = 460)
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
HbA1c 0.81 (0.23, 2.82) 0.74 0.52 (0.08, 3.31) 0.49 1.49 (0.50, 4.49) 0.48 7.85 (1.66, 37.14) 0.009
Platelet count 1.04 (1.00, 1.07) 0.03 1.02 (0.94, 1.10) 0.69 0.98 (0.95, 1.02) 0.35 1.01 (0.95, 1.08) 0.65
Platelet mass 0.996 (0.992, 0.999) 0.03 1.00 (0.94, 1.10) 0.66 1.00 (0.997, 1.005) 0.60 1.00 (0.991, 1.004) 0.52
MPV 2.46 (1.07, 5.61) 0.03 1.34 (0.18, 9.81) 0.77 0.78 (0.33, 1.85) 0.58 1.85 (0.44, 7.76) 0.40
The estimate indicates the hazard ratio (HR) with 95% confidence interval (CI) for every unit increase of the variable. The model was adjusted for age, sex,
waist-hip ratio, blood pressure (diastolic and systolic), cholesterol (total, HDL, LDL), smoking status (categorized: non-smoker, former smoker, current smoker),
alcohol intake (categorized: ≥20 g/day for women; ≥40 g/day for men), physical activity (categorized: >1 h per week).
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The role of GPIIIa polymorphism in genetic susceptibility
to clinical thrombotic disease still remains controversial
[18,19]. The results of case–control association studies
point to different directions, even within the same ethnic
groups, and the association was hardly found in studiesFigure 1 Multivariate adjusted hazards ratio of mortality by category
pre-diabetes and diabetes follows definition criteria of the American Diabetes
are given for each decile of HbA1c level (≤5% (31 mmol/mol), 5.1% (32 mmol/
5.5% (37 mmol/mol), 5.6% (38 mmol/mol), 5.7% (39 mmol/mol), 5.8% (40 mmo
taking HbA1c = 5.5% (37 mmol/mol) as the reference. The position of the
in the decile. The model was adjusted for age, sex, waist-hip ratio, RR dia
smoking status (categorized: non-smoker, former smoker, current smoker
men), physical activity (categorized: >1 h per week), platelet mass, meanwith larger sample size [18,31]. Whether there is an asso-
ciation between PLA-polymorphism and survival or
cardiovascular outcome cannot be answered finally. Cur-
rent available genome wide association studies (GWAS)
data on platelet reactivity were recently summarized by
Kuniki and Nugent [32]. Mesinger et al. evaluated inof HbA1c level in people with different genotypes. Definition of
Association (ADA) (20). The hazard ratios and 95% confidence interval
mol)/5.2% (33 mmol/mol), 5.3% (34 mmol/mol), 5.4% (36 mmol/mol),
l/mol), 5.9% (41 mmol/mol)/6.0% (42 mmol/mol), >6.5% (48 mmol/mol)),
points on the x-axis represents the median value of baseline HbA1c
stolic, RR systolic, total cholesterol, HDL cholesterol, LDL cholesterol,
), alcohol intake (categorized: ≥20 g/day for women; ≥40 g/day for
plate volume and platelet count.
Table 5 Multivariate adjusted hazards ratio of mortality
according to different categories of HbA1c level in people
with different genotypes
RR (95% CI)
Categories of HbA1c level Genotype: A1A1 Genotype: AxA2
<5% (<31 mmol/mol) 0.85 (0.34, 2.09) 1.68 (0.51, 5.61)
5.1/5.2% (32/33 mmol/mol) 1.29 (0.66, 2.52) 0.77 (0.18, 3.27)
5.3% (34 mmol/mol) 1.03 (0.48, 2.21) 1.18 (0.31, 4.51)
5.4% (36 mmol/mol) 0.80 (0.36, 1.78) 1.34 (0.38, 4.72)
5.5% (37 mmol/mol) 1 1
5.6% (38 mmol/mol) 0.85 (0.42, 1.72) 0.51 (0.12, 2.18)
5.7% (39 mmol/mol) 1.23 (0.64, 2.39) 1.31 (0.43, 3.99)
5.8% (40 mmol/mol) 0.69 (0.29, 1.64) 1.62 (0.46, 5.69)
5.9/6.0% (41/42 mmol/mol) 0.99 (0.49, 1.99) 1.37 (0.44, 4.28)
>6.5% (>48 mmol/mol) 1.35 (0.73, 2.51) 2.97 (1.07, 8.24)
The hazard ratios and 95% confidence interval are given for each decile of HbA1c
level (≤5% (31 mmol/mol), 5.1% (32 mmol/mol)/5.2% (33 mmol/mol), 5.3%
(34 mmol/mol), 5.4% (36 mmol/mol), 5.5% (37 mmol/mol), 5.6% (38 mmol/mol),
5.7% (39 mmol/mol), 5.8% (40 mmol/mol), 5.9% (41 mmol/mol)/6.0% (42 mmol/
mol), >6.5% (48 mmol/mol)), taking HbA1c = 5.5% (37 mmol/mol) as the
reference. The model was adjusted for blood pressure (diastolic and systolic),
cholesterol (total, HDL, LDL), smoking status (categorized: non-smoker,
former smoker, current smoker), alcohol intake (categorized: ≥20 g/day for
women; ≥40 g/day for men), physical activity (categorized: >1 h per week),
platelet mass, mean plate volume and platelet count.
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500 K Gene Chip analysis and did a replication in the
KORA S4 cohort, which is topic of this publication.
They found in KORA F3 3 common SNPs being strongly
associated with MPV, but PLA1A2 was not among
these [33]. Following a functional genomics approach no
association was found between PLA1A2 polymorphism
and platelet response parameters which might be caused
by a low minor allele frequency (MAF) of 0.15 of the SNP
and the studies conducted so far being underpowered
to show effects of SNPs with such low MAF [32,33]. In
another GWAS analysis done by Weiss et al. the ITGB3
polymorphism was identified as a quantitative trait locus
(QTL) for whole blood serotonin. Whether this is of
impact for platelet activation and platelet function has
not yet been examined [34].
PLA2 and its role in diabetes mellitus and prediabetes
Our data do not suggest an overall linkage between
PLA1A2 genotype and all-cause mortality but put further
substance to the assumption that the PLA2 SNP is as-
sociated with impaired metabolic control in diabetes
mellitus. In the group of non-diabetics with higher HbA1c
(HbA1c > 5.5% (37 mmol/mol) to <6.5% (48 mmol/mol))
including prediabetic subjects, people with PLA2 SNP
showed higher mortality risk for same increase of HbA1c
level compared to persons with HbA1c ≤ 5.5% (37 mmol/
mol), pointing to a combined effect of HbA1c and AxA2
genotype in this subgroup. This effect was not detected inA1A1 subjects. HbA1c had no significant influence on
survival in the diabetic patients of KORA; this might be
due to the limited number of subjects with elevated
HbA1c in this cohort.
HbA1c turned out to be a strong predictor for survival
in the non-diabetic population of the KORA cohort with
the lowest risk at a baseline level of 5.5% (37 mmol/
mol). This finding is in line with a previous publication
by Kowall et al. regarding KORA S4 participants aged
from 55 to 75 years [28]. Within the present analysis all
participants of KORA S4, whose survival status and whose
PLA1A2 genotype is known were included. Hyperglycemia
is a strong predictor of mortality and cardiovascular risk
and most of the observational studies show a linear positive
association [35-37]. However, some other studies - like
ours excluding manifest diabetics - suggest non-linear
relationships (U- or J-shaped) between glycemic status
and mortality risk [38-41]. These differences may rely on
the characteristics of the study population and confound-
ing factors (co-medication, diabetes duration, etc.). The
KORA S4-cohort has a small number of diabetic subjects
(N = 209; 5.2%) and a low overall mortality rate (5.9%).
J- and U-shaped relationships of HbA1c with overall
mortality are seen in population studies without diabetes
like the ARIC (Atherosclerosis Risk in Communities)
study [39] and National Health and Nutrition Examin-
ation Survey (NHANES) [41] pointing to the possible
effects of comorbidities and age or other yet unknown
confounders, which might be similar to the KORA
S4-cohort. A study involving diabetes patients showed
U-shaped mortality curves with increasing HbA1c values
and optimal HbA1c with lowest mortality events around
7.5% [40]; the higher mortality associated with low HbA1c
may be attributable to the level of comorbidities [42].
Our results may imply that non-diabetic people with
AxA2 are more sensitive to the level of HbA1c, and suffer
higher relative risk of mortality than people with A1A1
genotype for the same increase of HbA1c level in the range
of 5.5% (37 mmol/mol) to 6.5% (48 mmol/mol), resem-
bling a prediabetic metabolic situation. The association
of HbA1c and all-cause of death was PLA1A2 genotype
specific. At each decile the curve of AxA2 carriers is
shifted to elevated hazard ratios, while in people with
A1A1 the HbA1c level was not significantly associated
with mortality (Table 3). The curve presented in Figure 1
showing the hazards ratio for each HbA1c decile documents
the higher risk of AxA2 carriers with increasing HbA1c.
In this special constellation mortality obviously seems
to be driven by the more thrombogenic AxA2 allele.
Platelet functional markers and the prediction of survival
in healthy people
An important additional finding on survival prediction in
our analysis is that MPV, platelet count and platelet mass
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with HbA1c less than 5.5% (37 mmol/mol). This fact
clearly points to the role of platelet characteristics in the
group of definite non-diabetics, contributing to survival/
mortality. In this cohort subjects with AxA2 genotype
present with significant lower MPV but preserved platelet
mass, which might be an indicator of increased platelet
consumption, mainly of the larger platelet-subpopulation
that present more receptors per platelet [23]. Due to
slightly higher numbers in platelet count this effect may
be compensated by keeping the platelet mass constant
to sustain regular functionality. Besides elevated age,
smoking, alcohol consumption, platelet morphology and
mass may contribute to the higher mortality risk in these
individuals.
Conclusion
PLA2 significantly correlates with mortality in non-
diabetics with HbA1c values of >5.5% (37 mmol/mol)
up to 6.5% (48 mmol/mol), including the prediabetic
subjects. Therefore, even the prediabetic subject has to
be regarded as a vulnerable vascular patient, which has
recently been confirmed by the Silent Diabetes Study,
published by Doerr and co-authors [43]. Elevated blood
glucose levels beyond the diabetic threshold are a
powerful predictor of 30 day mortality in acute heart
failure patients, emphasizing the critical role of the pre-
diabetic state [44]. Our results suggest the need for a
graded interventional hierarchy supporting antiplatelet
therapy in nondiabetics, maintenance of euglycemia and
antiplatelet therapy in prediabetic AxA2 subjects whereas
in manifest diabetes euglycemia is recommended as the
most important therapeutic aim.
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